levoleucovorin calcium / Generic mfg. - LARVOL DELTA

A phase II study of bTAE-HAIC combined with lenvatinib and camrelizumab for patients with high tumor burden hepatocellular carcinoma: The TALEM-H trial. (ASCO 2026) - P=N/A | " Forty patients with huge HCC (defined as a single tumor >10 cm or multiple tumors >15 cm in diameter) received bTAE and FOLFOX-HAIC (Oxaliplatin 85mg/m2 2h + Calcium Levofolinate 400mg/m2 2h + Fluorouracil 2400mg/m2 46h) and lenvatinib (4-8mg) once daily plus camrelizumab (200mg) Q3W... bTAE-HAIC combined with lenvatinib plus camrelizumab represents a promising first-line treatment, offering an exceptional ORR and encouraging survival outcomes for HCC patients with a high tumor burden. Baseline characteristics."

Clinical • P2 data • Hematological Disorders • Hepatocellular Cancer • Oncology • Pneumonia • Solid Tumor

Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): OS analysis results of the SYLT-023. (ASCO-GI 2025) - P1/2 | "The combination of Tisle + XELOX/FP is a first-line treatment of AGC in China... Tisle+POFI was well tolerated and showed preliminary antitumor activity in AGC. A phase II study is ongoing."

Clinical • Metastases • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • HER-2 • PD-L1

Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin, and 5-FU/levoleucovorin) as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Update from a single-arm, open-label phase II trial (SYLT-023). (ASCO-GI 2026) - P1/2 | "Background: A Phase I study demonstrated that tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin, 5-fluorouracil/levoleucovorin) was tolerable with promising antitumor activity as first-line treatment for HER2-negative, proficient mismatch repair (pMMR)/microsatellite stable (MSS) advanced gastric/gastroesophageal junction adenocarcinoma (AGC) (Lin R, et al. Tisle + POFI showed promising efficacy and a manageable safety profile as first-line treatment for HER2-negative, pMMR/MSS AGC, warranting further investigation."

Clinical • Metastases • P2 data • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • HER-2 • PD-L1

Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin, and 5-FU/levoleucovorin) as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Update from a single-arm, open-label phase I/II trial (SYLT-023). (ASCO 2026) - P1/2 | "The combination of Tisle + XELOX/FP is a first-line treatment of AGC in China... Tisle + POFI showed promising efficacy and a manageable safety profile as first-line treatment for HER2-negative, pMMR/MSS AGC, warranting further investigation."

Clinical • Metastases • P1/2 data • Gastric Adenocarcinoma • Gastroesophageal Junction Adenocarcinoma • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Solid Tumor • HER-2 • PD-L1

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. (PubMed, Lancet) - P3 | "Targeting CLDN18.2 with zolbetuximab significantly prolonged progression-free survival and overall survival when combined with mFOLFOX6 versus placebo plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Zolbetuximab plus mFOLFOX6 might represent a new first-line treatment in these patients."

Journal • Metastases • P3 data • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18 • HER-2

Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial. (PubMed, Lancet Oncol) - P2 | "The addition of bevacizumab did not seem to increase the benefit of FOLFIRI with regard to overall survival. FOLFIRI could be considered as a standard second-line treatment in patients with gastroenteropancreatic neuroendocrine carcinoma."

Journal • Metastases • P2 data • Cardiovascular • Endocrine Cancer • Hematological Disorders • Ischemic stroke • Neuroendocrine Tumor • Neutropenia • Oncology • Pancreatic Cancer • Solid Tumor

A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation (clinicaltrials.gov) - P2 | N=50 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P2 trial • Colorectal Cancer • Oncology • Solid Tumor • KRAS

A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: Ono Pharmaceutical Co., Ltd.

New P3 trial • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Oncology • Solid Tumor • PD-L1

Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018). (PubMed, J Clin Oncol) - "No benefit of adding OX to FP + BEV as first-line treatment was demonstrated in older patients with MCRC. FP + BEV is recommended for this population."

Journal • Metastases • P3 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer (clinicaltrials.gov) - P3 | N=300 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Oncology • Solid Tumor

GAIA-102-PD: GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites (clinicaltrials.gov) - P1/2 | N=176 | Recruiting | Sponsor: Kyushu University | N=130 ➔ 176 | Trial completion date: Mar 2029 ➔ Mar 2032 | Trial primary completion date: Dec 2028 ➔ Mar 2032

Enrollment change • Trial completion date • Trial primary completion date • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CXCL11 • HER-2

A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) (clinicaltrials.gov) - P2 | N=480 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

Monotherapy • New P2 trial • Oncology • Solid Tumor

Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b). (ASCO 2025) - P1, P3 | "Discontinuation of sotorasib, panitumumab, or FOLFIRI (5-FU, irinotecan, or leucovorin/levoleucovorin) due to AEs was observed in 1 (2.5%), 1 (2.5%), and 16 (40.0%) patients, respectively... Sotorasib plus panitumumab and FOLFIRI showed promising long-term safety and efficacy in pretreated KRAS G12C-mutated mCRC. AEs were consistent with the safety profile of the drugs administered. The ongoing phase 3 study, CodeBreaK 301 (NCT06252649), aims to evaluate this combination against standard of care in first-line patients with KRAS G12C-mutated mCRC."

Clinical • Metastases • P1 data • Colorectal Cancer • Dental Disorders • Dermatitis • Dermatology • Immunology • Oncology • Solid Tumor • Stomatitis • KRAS

AALL1631: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P3 | N=352 | Active, not recruiting | Sponsor: Children's Oncology Group | Trial primary completion date: Sep 2027 ➔ Jun 2026

Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • ABL1 • CSF1R • PDGFRA • PDGFRB

Leucovorin Versus Levoleucovorin Rescue After High-dose Methotrexate in Central Nervous System Lymphoma. (PubMed, Anticancer Res) - "In this study of patients with PCNSL or SCNSL receiving high-dose methotrexate, the use of levoleucovorin in place of leucovorin during a supply interruption was not associated with worse short-term safety outcomes and was associated with lower rescue utilization and direct rescue drug cost in our setting."

Clinical • Journal • Retrospective data • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Thrombocytopenia

A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) (clinicaltrials.gov) - P3 | N=538 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

OrigAMI-3: A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy (clinicaltrials.gov) - P3 | N=700 | Recruiting | Sponsor: Janssen Research & Development, LLC

New P3 trial • Colorectal Cancer • Oncology • Solid Tumor • BRAF

OrigAMI-2: A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (clinicaltrials.gov) - P3 | N=1000 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Dec 2032 ➔ Jan 2032

Trial completion date • Colorectal Cancer • Oncology • Solid Tumor • BRAF • KRAS • NRAS • RAS

OrigAMI-2: A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (clinicaltrials.gov) - P3 | N=1000 | Recruiting | Sponsor: Janssen Research & Development, LLC | Not yet recruiting ➔ Recruiting | Trial completion date: Jan 2032 ➔ Dec 2032

Enrollment open • Metastases • Trial completion date • Colorectal Cancer • Oncology • Solid Tumor • BRAF

OrigAMI-2: A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (clinicaltrials.gov) - P3 | N=1000 | Not yet recruiting | Sponsor: Janssen Research & Development, LLC

Metastases • New P3 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF

A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure (clinicaltrials.gov) - P3 | N=398 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

LIBImAb: Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB (clinicaltrials.gov) - P3 | N=280 | Active, not recruiting | Sponsor: Azienda USL Reggio Emilia - IRCCS | Recruiting ➔ Active, not recruiting | Trial completion date: May 2026 ➔ Dec 2026

Enrollment closed • Liquid biopsy • Trial completion date • Colorectal Cancer • Oncology • Solid Tumor • BRAF

A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (clinicaltrials.gov) - P3 | N=477 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P3 trial • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Solid Tumor • KRAS

A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (clinicaltrials.gov) - P3 | N=477 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial primary completion date: Aug 2029 ➔ Mar 2029

Trial primary completion date • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Solid Tumor • KRAS

A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (clinicaltrials.gov) - P3 | N=477 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Solid Tumor • KRAS